{"title":"在放疗的基础上增加化疗与老年宫颈癌患者生存率的提高有关:一项监测、流行病学和最终结果数据库分析。","authors":"Kittinun Leetanaporn, Jitti Hanprasertpong","doi":"10.1016/j.ijgc.2025.101633","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We evaluated the effectiveness of chemoradiation compared with radiotherapy alone in older patients with cervical cancer and determined the age sub-group wherein chemotherapy loses its significance using the Surveillance, Epidemiology, and End Results database.</p><p><strong>Methods: </strong>Women aged ≥65 years with cervical cancer who received definitive radiotherapy or chemoradiation were identified on the basis of the 2000-2019 Surveillance, Epidemiology, and End Results data. Overall and cancer-specific survival were compared in treatment groups, with survival prognostic factors assessed using multivariate analysis. Exploratory sub-group analyses at 5-year age increments determined the age threshold at which chemotherapy benefits became non-significant, with a multivariate p value ≥ .05 indicating reduced impact on overall and cancer-specific survival.</p><p><strong>Results: </strong>A total of 1832 patients were included in the study. Of these, 563 patients received radiotherapy, and 1269 patients received chemoradiation. The median age of the cohort was 74 years (Q1-Q3, 69.00-80.00). The 5-year overall and cancer-specific survival rates were 40.52% and 53.47%, respectively. In the multivariate analysis, chemotherapy significantly improved both overall (HR 0.47, p < .001) and cancer-specific (HR 0.57, p < .001) survival. For cancer-specific survival, the chemotherapy benefits progressively decreased with age, remaining significant until the age of >75 years (HR 0.63, p < .001) and decreasing after the age of 80 years (HR 0.79, p = .12). However, for overall survival, the chemotherapy benefit was observed in all age groups, except for patients aged >85 years (HR 0.72, p = 0.14).</p><p><strong>Conclusions: </strong>Chemotherapy was beneficial for women aged ≥65 years with cervical cancer who underwent radiotherapy. However, in patients aged >80 years, chemotherapy had no significant impact on cancer-specific survival.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101633"},"PeriodicalIF":4.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Addition of chemotherapy to radiation is associated with improved survival in older patients with cervical cancer: a Surveillance, Epidemiology, and End Results database analysis.\",\"authors\":\"Kittinun Leetanaporn, Jitti Hanprasertpong\",\"doi\":\"10.1016/j.ijgc.2025.101633\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>We evaluated the effectiveness of chemoradiation compared with radiotherapy alone in older patients with cervical cancer and determined the age sub-group wherein chemotherapy loses its significance using the Surveillance, Epidemiology, and End Results database.</p><p><strong>Methods: </strong>Women aged ≥65 years with cervical cancer who received definitive radiotherapy or chemoradiation were identified on the basis of the 2000-2019 Surveillance, Epidemiology, and End Results data. Overall and cancer-specific survival were compared in treatment groups, with survival prognostic factors assessed using multivariate analysis. Exploratory sub-group analyses at 5-year age increments determined the age threshold at which chemotherapy benefits became non-significant, with a multivariate p value ≥ .05 indicating reduced impact on overall and cancer-specific survival.</p><p><strong>Results: </strong>A total of 1832 patients were included in the study. Of these, 563 patients received radiotherapy, and 1269 patients received chemoradiation. The median age of the cohort was 74 years (Q1-Q3, 69.00-80.00). The 5-year overall and cancer-specific survival rates were 40.52% and 53.47%, respectively. In the multivariate analysis, chemotherapy significantly improved both overall (HR 0.47, p < .001) and cancer-specific (HR 0.57, p < .001) survival. For cancer-specific survival, the chemotherapy benefits progressively decreased with age, remaining significant until the age of >75 years (HR 0.63, p < .001) and decreasing after the age of 80 years (HR 0.79, p = .12). However, for overall survival, the chemotherapy benefit was observed in all age groups, except for patients aged >85 years (HR 0.72, p = 0.14).</p><p><strong>Conclusions: </strong>Chemotherapy was beneficial for women aged ≥65 years with cervical cancer who underwent radiotherapy. However, in patients aged >80 years, chemotherapy had no significant impact on cancer-specific survival.</p>\",\"PeriodicalId\":14097,\"journal\":{\"name\":\"International Journal of Gynecological Cancer\",\"volume\":\" \",\"pages\":\"101633\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gynecological Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijgc.2025.101633\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijgc.2025.101633","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/9 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:我们通过监测、流行病学和最终结果数据库评估放化疗与单独放疗在老年宫颈癌患者中的有效性,并确定化疗失去意义的年龄亚组。方法:根据2000-2019年的监测、流行病学和最终结果数据,确定年龄≥65岁接受最终放疗或放化疗的宫颈癌女性。比较治疗组的总生存率和癌症特异性生存率,并使用多变量分析评估生存预后因素。5岁时的探索性亚组分析确定了化疗益处变得不显著的年龄阈值,多变量p值≥0.05表明对总体和癌症特异性生存的影响降低。结果:共纳入1832例患者。其中,563名患者接受了放疗,1269名患者接受了放化疗。队列的中位年龄为74岁(Q1-Q3, 69.00-80.00)。5年总生存率为40.52%,肿瘤特异性生存率为53.47%。在多变量分析中,化疗显著提高了总生存率(HR 0.47, p < 0.001)和癌症特异性生存率(HR 0.57, p < 0.001)。对于癌症特异性生存,化疗获益随着年龄的增长而逐渐下降,直到75岁(HR 0.63, p < .001), 80岁后下降(HR 0.79, p = .12)。然而,对于总生存期而言,除bb0 ~ 85岁患者外,所有年龄组均观察到化疗获益(HR 0.72, p = 0.14)。结论:化疗对年龄≥65岁的宫颈癌放疗妇女是有益的。然而,在bb0 ~ 80岁的患者中,化疗对癌症特异性生存没有显著影响。
Addition of chemotherapy to radiation is associated with improved survival in older patients with cervical cancer: a Surveillance, Epidemiology, and End Results database analysis.
Objective: We evaluated the effectiveness of chemoradiation compared with radiotherapy alone in older patients with cervical cancer and determined the age sub-group wherein chemotherapy loses its significance using the Surveillance, Epidemiology, and End Results database.
Methods: Women aged ≥65 years with cervical cancer who received definitive radiotherapy or chemoradiation were identified on the basis of the 2000-2019 Surveillance, Epidemiology, and End Results data. Overall and cancer-specific survival were compared in treatment groups, with survival prognostic factors assessed using multivariate analysis. Exploratory sub-group analyses at 5-year age increments determined the age threshold at which chemotherapy benefits became non-significant, with a multivariate p value ≥ .05 indicating reduced impact on overall and cancer-specific survival.
Results: A total of 1832 patients were included in the study. Of these, 563 patients received radiotherapy, and 1269 patients received chemoradiation. The median age of the cohort was 74 years (Q1-Q3, 69.00-80.00). The 5-year overall and cancer-specific survival rates were 40.52% and 53.47%, respectively. In the multivariate analysis, chemotherapy significantly improved both overall (HR 0.47, p < .001) and cancer-specific (HR 0.57, p < .001) survival. For cancer-specific survival, the chemotherapy benefits progressively decreased with age, remaining significant until the age of >75 years (HR 0.63, p < .001) and decreasing after the age of 80 years (HR 0.79, p = .12). However, for overall survival, the chemotherapy benefit was observed in all age groups, except for patients aged >85 years (HR 0.72, p = 0.14).
Conclusions: Chemotherapy was beneficial for women aged ≥65 years with cervical cancer who underwent radiotherapy. However, in patients aged >80 years, chemotherapy had no significant impact on cancer-specific survival.
期刊介绍:
The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.